Abstract:Objectives To evaluate the difference between low-molecular-weight heparin (LMWH) and aspirin in preventing early neurological deterioration (END) and recurrent ischemic stroke (RIS), post-recovery independence, and safety outcomes in acute ischemic stroke. Materials and Methods We performed systematic searches of the PubMed, Embase, Web of Science, and Cochrane Library databases for full-text articles of randomized controlled trials (RCTs) of LMWH vs. aspirin in the early management of acute ischemic stroke. Information on study design, eligibility criteria, baseline information, and outcomes was extracted. Synthesized relative risks (RRs) with 95% confidence intervals (CIs) are used to present the differences between the two treatments based on fixed-effects models. Results Five RCTs were retrieved from the online databases. The results showed no significant difference in efficacy outcomes between the two groups among unselected patients. Subgroup analysis showed that LMWH was significantly related to a lower incidence of END events [relative risk (RR): 0.44, 95% confidence interval (CI): 0.35–0.56] and reduced occurrence of RIS during treatment (OR: 0.34, 95% CI: 0.16–0.75) in non-cardioembolic stroke. LMWH significantly increased the number of patients with a modified Rankin scale (mRS) score of 0–1 at 6 months in patients with large-artery occlusive disease (LAOD) (RR: 0.50, 95% CI: 0.27–0.91). LMWH had a similar effect on symptomatic intracranial hemorrhage (sICH) and major extracranial hemorrhage during treatment to that of aspirin, except that LMWH was related to an increased likelihood of extracranial hemorrhage. Conclusions In patients with acute non-cardioembolic ischemic stroke, especially that with large-artery stenosis, LMWH treatment significantly reduced the incidence of END and RIS, and improved the likelihood of independence (mRS 0–1) at 6 months compared with those with aspirin treatment. LMWH was related to an increased likelihood of extracranial hemorrhage among all patients; however, the difference in major extracranial hemorrhage and sICH was not significant. Choosing the appropriate patients and paying attention to the start time and duration of treatment are very important in the use of anticoagulation. Systematic Review Registration http://www.crd.york.ac.uk/PROSPERO , identifier CRD42020185446.

Multicenter Clinical Trial on Low Molecular Weight Heparin Acute Anticoagulation Before Immediate Conversion in the Treatment of Atrial Fibrillation and Atrial Flutter

[Efficacy and Safety of Ibutilide for Conversion of Atrial Fibrillation/flutter].

Comparison of Converting Efficacy and Safety of Intravenous Ibutilide and Propafenone in Chinese Patients with Atrial Fibrillation and Atrial Flutter

Immediate cardioversion of atrial fibrillation and atrial flutter lasting less than 90 days by ibutilide versus propafenone: a multicenter study]

Influence of Atrial Fibrillation on Intravenous Thrombolysis of Acute Ischemic Stroke Patients Within Different Time Window

Randomized Study of Efficiency and Safety of Antithrombotic Therapy with Warfarin in Nonvalvular Atrial Fibrillation

Clinical Comparison of Ibutilide and Propafenone for Converting Atrial Flutter.

Efficacy and safety of short-term initiation of new oral anticoagulants in perioperative period of ablation for atrial fibrillation

Clinical Outcomes of Bridging Therapy with Fondaparinux Versus Low-Molecular-weight Heparin in Patients Undergoing Atrial Fibrillation Ablation.

Effectiveness and Safety of Ibutilide in Treating Atrial Fibrillation and Atrial Flutter:A Systematic Review

Clinical comparison of ibutilide and propafenone for the termination of atrial fibrillation/atrial flutter

Clinical Outcomes of Bivalirudin Versus Heparin in Atrial Fibrillation Patients Undergoing Percutaneous Left Atrial Appendage Occlusion

Optimal Initial Duration of Low Molecular Weight Heparin Lead-in Before Direct Oral Anticoagulants for Short-Term Outcomes of Hospitalized Patients with Non-High-risk Acute Pulmonary Embolism.

Safety of Preoperative Heparin for Prevention of Thrombus in Patients Undergoing Thoracoscopic Surgery

Low-Molecular-Weight Heparin Versus Aspirin in Early Management of Acute Ischemic Stroke: A Systematic Review and Meta-Analysis

Efficacy of Wenxin Keli Plus Amiodarone versus Amiodarone Monotherapy in Treating Recent-Onset Atrial Fibrillation

Comparison of Intravenous Ibutilide Vs. Propafenone for Rapid Termination of Recent Onset Atrial Fibrillation*

Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment

Efficacy and safety of early anticoagulation after endovascular treatment in patients with atrial fibrillation

Efficacy and speed of conversion of recent onset atrial fibrillation using oral propafenone versus parenteral amiodarone: A randomized controlled comparative study

Effect of Different Initial Anticoagulant Strategies on Short‐term Outcome of Patients with Symptomatic DVT in China